Data on berotralstat as treatment for HAE to be presented at 2025 ACAAI Annual Scientific Meeting

[Berotralstat is also often referred to by its brand name, Orladeyo]

Four abstracts on berotralstat, used as a treatment for HAE, will be presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, USA from 6-10 November 2025.

The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily berotralstat in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years, as well as findings on the psychosocial impact of HAE on young patients and their caregivers.

(Source: BioCryst)